US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results

Yahoo FinanceMar 5 05:32 ET

Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $11.5

Moomoo NewsMar 4 07:34 ET · Ratings

Analyst Expectations For Myriad Genetics's Future

BenzingaMar 3 14:01 ET

Myriad Genetics Is Maintained at Underperform by B of A Securities

Dow JonesMar 3 08:28 ET · Ratings

Express News | Myriad Genetics Inc : BofA Global Research Cuts Price Objective to $11 From $13

ReutersMar 3 06:08 ET

Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes

TipRanksMar 2 01:01 ET

Myriad Genetics | 10-K: FY2024 Annual Report

SECFeb 28 16:06 ET · Announcements

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

GlobeNewswireFeb 27 16:15 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Quest Diagnostics (DGX) and Myriad Genetics (MYGN)

TipRanksFeb 27 04:50 ET · Ratings

A Quick Look at Today's Ratings for Myriad Genetics(MYGN.US), With a Forecast Between $11 to $19

Moomoo NewsFeb 26 08:00 ET · Ratings

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Released Its Yearly Earnings: Here's What Analysts Think

Simply Wall StFeb 26 07:17 ET

Myriad Genetics Reports Strong Growth Amid Challenges

TipRanksFeb 25 19:25 ET

Express News | Myriad Genetics Shares Are Trading Lower Following a Q4 Revenue Miss and FY25 Revenue Guidance Below Estimates. The Stock May Also Be Trading on Weakness After It Announced It Will Face Cost Restructuring Following UnitedHealthcare's Decision to End...

BenzingaFeb 25 15:03 ET

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

BenzingaFeb 25 14:22 ET

Why Myriad Genetics (MYGN) Shares Are Plunging Today

Yahoo FinanceFeb 25 14:07 ET

Myriad Genetics Is Maintained at Neutral by UBS

Dow JonesFeb 25 10:26 ET · Ratings

Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer

Yahoo FinanceFeb 25 10:25 ET

Myriad Genetics Analyst Ratings

BenzingaFeb 25 10:15 ET · Ratings

Cautious Outlook for Myriad Genetics Amid Leadership Transition and Revised Growth Projections

TipRanksFeb 25 08:58 ET

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Underwhelming Economic Data, Renewed Trade Tensions

MT NewswiresFeb 25 08:33 ET